A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
This study is testing a new experimental drug called NVL-330 for people with a specific type of lung cancer known as HER2-altered non-small cell lung cancer (NSCLC). Researchers want to see if this new medicine is safe and if it can effectively stop or shrink tumors that have spread.
You may be eligible if you are 18 or older and have been diagnosed with advanced or metastatic non-small cell lung cancer that has a specific HER2 gene mutation. You must not be currently receiving other cancer treatments and your doctors must be able to track your tumor progress through scans.
Participants will receive the experimental drug NVL-330 while doctors closely monitor their safety and the drug's effect on their cancer. The study starts by finding the best dose for patients and then continues to see how well that dose works to fight the cancer.
The study is currently recruiting patients at medical centers in Irvine, Sacramento, and Stanford, California. Because it is a clinical trial, you would have regular check-ups at these specific locations.
- 1Testing a new targeted therapy called NVL-330 for HER2-altered lung cancer.
- 2Aims to determine the safest and most effective dose for future patients.
- 3Available for adults with advanced cancer that has spread locally or to other parts of the body.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.